^
    Back
    Association details:
    Biomarker:CD8 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Immunol
    Title:

    Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

    Published date:
    12/21/2023
    Excerpt:
    In NSCLC tissues, higher expression of CXCL13 was associated with better clinical outcomes (P=0.032) and higher expression of CD8 was associated with prolonged survival (P=0.022).
    DOI:
    10.3389/fimmu.2023.1276107